The JV offers an opportunity to rapidly scale up volumes and its approval has therefore led to sharp upgrades to Dixon’s revenue and earnings estimates.
While near-term upside may be limited, given that the stock, at ₹13,420, has gained 17 per cent over the past month and 29 per cent over the past three months, the JV also offers backward integration opportunities and, consequently, the potential for higher margins.
The biggest upside from the JV is the significant increase in volumes. Vivo, which commands a 23 per cent market share in India, ended CY25 with volumes of 35 million units.
The company expects the JV to handle about two-thirds of this volume, translating into an annual addition of around 22 million units. Given that production is expected to begin about 40 days after the approval, the full revenue and volume benefits are likely to materialise from the December quarter.
According to the management, the JV could add ₹30,000 crore to revenue, supported by higher average selling prices than Dixon’s existing mobile portfolio. JP Morgan Research expects the JV to contribute 11 million mobile units in 2026-27 (FY27) and 22 million units each in FY28 and FY29.
The brokerage has raised its revenue estimates by 24-39 per cent for FY27-29, while earnings per share estimates have been upgraded by a relatively lower 13–18 per cent because of the 51:49 JV structure, which results in minority interest.
It has an overweight rating with a target price of ₹16,700, compared with ₹14,300 earlier.
The Vivo JV could materially increase Dixon’s mobile phone volumes from 32 million to about 55 million units, creating a stable revenue stream for the mobile segment. Beyond Vivo, the EMS major also has opportunities, particularly in exports.
Manish Choraghe of Keynote Capitals said Dixon is exploring export opportunities in Africa through its Ismartu subsidiary and through a JV with Longcheer. Continued momentum from its existing large US customer is also expected to strengthen its export revenue profile.
Collectively, Dixon’s mobile business remains well anchored, with client stickiness and scale being its two most durable competitive advantages, he added. The brokerage has a buy rating with a target price of ₹16,608.
Apart from higher volumes, Dixon’s focus on backward integration and expansion into specialised EMS verticals is expected to reduce cyclicality and improve margins.
Motilal Oswal Research pointed out that the company is investing in backward integration for display and camera modules. Teena Virmani and Prerit Jain of the brokerage expect the benefits of these initiatives to start accruing from H2FY27.
By FY28, they expect backward integration to more than offset the margin contraction arising from the end of the production linked incentive (PLI) 1.0 scheme this year.
For the June quarter, however, the brokerage expects operating profit margins to contract by 50 basis points year-on-year to 3.3 per cent as mobile PLI incentives cease, although an improved revenue mix across segments should limit the decline. It has a target price of ₹16,100.
Among the key growth catalysts are continued policy support for domestic electronics manufacturing, including the mobile PLI 2.0 scheme.
Diversification into other EMS verticals such as aerospace, automotive, defence, medical and industrial electronics should also help broaden revenue streams, reduce dependence on consumer businesses and improve margins.
Emkay Research believes Dixon’s strong return ratios, negative working capital cycle and robust cash generation justify its premium valuation. The brokerage has a buy rating with a target price of ₹15,200.
 "tsi")